Definitive Contract 75F40123C00140
Award Date 9/18/23
Potential Completion Date 6/24/25
Potential Value $263K
Federal Agency
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Schenectady, NY 12305, USA
Solicitation Procedures
Two Step
Number Of Offers Received
1
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This $291,618 definitive contract was awarded by the Food and Drug Administration (FDA) to the Institute For Clinical Pharmacodynamics, Inc. (ICPI), a for-profit, minority-owned organization. The contract is in support of the FDA's Combatting Antibiotic Resistant Bacteria (CARB) program and will have a period of performance through September 29, 2023. Under this contract, ICPI will provide pharmacometric analysis and modeling services to the FDA to support updating clinical breakpoints for the...
- This contract award is for the Drug Manufacturing and Formulation Program (DMFP), an Indefinite Delivery Indefinite Quantity (IDIQ) contract with Albany Molecular Research Inc. The purpose is to de-obligate unexpended and expiring fiscal year 2020 funding in preparation for the closure of the period of availability for these funds. The contract has a ceiling value of $1,865,351.12 and was awarded on September 10, 2019, with an ultimate completion date of September 12, 2024. The prime...
- This $399,991 federal contract was awarded by the U.S. Food and Drug Administration (FDA) to Midwestern University, a private, non-profit educational institution, to develop and validate population pharmacokinetic models for beta-lactam antibiotics used in critical care settings, specifically to guide treatment for patients with hospital-acquired pneumonia. The contract is a definitive, cost-no-fee contract with a completion date of September 29, 2025. This contract was issued under a Broad...
- This is a new task order awarded under an existing Indefinite Delivery Indefinite Quantity (IDIQ) contract (HHSF223201610004I) with the Department of Health and Human Services Food and Drug Administration (FDA). The task order, valued at $2,470,791.00, is for a Pharmacokinetic (PK) study of opioid drug products following oral ingestion of chewed products. The study falls under the FDA's In Vivo Study of Generic Drug Products in Human Subjects program. The contract is a Firm Fixed Price...
- This is a definitive, firm-fixed-price contract awarded by the Food and Drug Administration (FDA), a civilian agency within the Department of Health and Human Services (HHS), to Akina, Inc., a minority-owned, for-profit, Asian-Pacific American manufacturer of research products and services. The $548,834 contract is for the development of advanced analytical techniques for mixed polymer drug-delivery systems, supporting the FDA's regulatory science and innovation goals. This contract, which has...
- The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a $554,127.00 Cost Plus Fixed Fee contract to Curia Global Inc., doing business as Amri, for the "SCALE UP FERMENTATION AND ISOLATION OF MEDINAMYCIN" effort. This is a Delivery Order issued under the Nonclinical Services for Development of Interventional Agents indefinite-delivery, indefinite-quantity (IDIQ) contract. Curia Global is a leading global...
- This is a firm-fixed-price purchase order contract awarded by the National Institutes of Health (NIH) Clinical Center, a civilian agency, to Tri-Pharma, Inc., a minority-owned, Hispanic American-owned small disadvantaged business corporation. The $15,500 contract is for the delivery of pharmaceutical and medical supply products, including items like SANDOSTATIN, RYDAPT, fludarabine, ranitidine, and personal protective equipment such as N95 masks, surgical masks, and disinfectant wipes. The...
- This is a delivery order awarded by the Department of Health and Human Services (HHS) Food and Drug Administration (FDA) to Palladian Partners, Inc., a for-profit company that specializes in health and science communications. The contract has a potential value of $901,743.54 and was issued under the General Services Administration's (GSA) Professional Services Schedule (PSS). It does not have a set-aside designation. Palladian Partners, a subsidiary of the nonprofit Altarum Institute, has been...
- This is a firm fixed price federal contract awarded by the Food and Drug Administration (FDA) to Akina, Inc., a minority-owned, for-profit, Asian-Pacific American manufacturer located in West Lafayette, Indiana. The contract, valued at $1,211,682.00, is for the development of new analytical methods for mini-size complex long-acting injectable formulations, specifically poly(lactide-co-glycolide) (PLGA) formulations. This contract aims to advance the FDA's regulatory science and innovation goals,...
- This is a $1,904,355.00 definitive cost-no-fee contract awarded by the Food and Drug Administration (FDA), a civilian government agency, to the Institute Of Quantitative Systems Pharmacology, a non-profit organization. The contract is for basic and applied research with two key objectives: (1) to test the hypothesis that variabilities in nanoparticle (NP) properties and tumor targets cause uncertainties in "FORMULA", and (2) to develop computational models to predict the...